The polyol pathway is a two-step route that turns glucose into fructose inside the body. Sorbitol is the halfway point. The polyol pathway is also called the sorbitol pathway. The second name comes from sorbitol, the sugar alcohol formed halfway through. Both terms describe the same two-step route.

Most of the time this pathway is quiet. Research suggests around 3% of circulating glucose goes through it. The rest is metabolized through glycolysis.

The pathway exists for a reason. It is understood to have evolved as a survival mechanism. Making fructose internally helps the body store fat and hold on to water. That was useful during shortage, dehydration or threat.

The problem is that the triggers are no longer occasional. High blood glucose, chronic stress and mild dehydration are common. A pathway built for short bursts now runs much of the time. The result is fructose made inside the body. It enters metabolism through the same door as dietary fructose and has the same effects.

Only two enzymes are involved. Both cost the cell something beyond the reaction itself.

Aldose reductase handles the first step. It turns glucose into sorbitol. It binds glucose weakly, which is why the pathway stays quiet at normal blood glucose and speeds up when glucose rises.

This step uses NADPH. That matters. NADPH is also what the cell uses to regenerate glutathione, its main built-in antioxidant. So the pathway lowers antioxidant capacity at the same time as it raises fructose production (Chung et al., 2003).

Sorbitol dehydrogenase handles the second step. It turns sorbitol into fructose and uses up NAD+. This shifts the balance between NADH and NAD+. Researchers call the resulting state pseudohypoxia. The cell behaves as though it is short of oxygen, even when oxygen supply is fine (Yan, 2018).

Some tissues are more exposed than others. The retina, the peripheral nerves, the kidney and the lens of the eye all take up glucose without needing insulin. They cannot limit how much glucose enters when blood levels rise.

Four conditions are linked to higher flow through the pathway.

High blood glucose. The main trigger. As glucose rises, the normal route saturates and more is diverted here.

Dehydration and high salt. Both raise the concentration of the blood. Research associates this with aldose reductase activation. That fits the pathway’s proposed role in conserving water.

Chronic stress. Stress hormones raise blood glucose, which feeds the pathway indirectly. Preliminary evidence points to direct effects on the enzymes as well.

Restricted blood flow. States of low blood flow or energy stress mimic the survival conditions the pathway evolved for.

None of these requires eating sugar. That is the practical point. Someone can cut dietary fructose substantially and still carry meaningful fructose exposure made internally.

Three effects overlap.

Antioxidant capacity falls: NADPH used by aldose reductase is NADPH not available for glutathione. The cell’s antioxidant reserve drops at the same moment the pathway is adding oxidative load. Research associates this combination with progressive damage in exposed tissues.

Pressure builds inside cells: Sorbitol does not leave cells easily. Where the pathway runs constantly, sorbitol collects and draws in water. This has been studied most in the lens of the eye and in nerve tissue.

Fructose reaches fructokinase: The fructose made at the end of the pathway is handled by fructokinase (KHK). That enzyme has no brake. ATP is used up. AMP builds. Xanthine oxidase converts it onward to uric acid. It is the same cascade that dietary fructose starts, now running on glucose that was never eaten as sugar.

These three effects feed each other. Oxidative stress impairs insulin signaling. Impaired insulin signaling raises blood glucose. Higher glucose pushes more flow through the pathway. It is a self-reinforcing cycle.

The polyol pathway is one of four mechanisms most often used to explain how high blood glucose damages tissue in diabetes. The others are advanced glycation end products, protein kinase C activation and the hexosamine pathway (Brownlee, 2001).

Diabetic retinopathy: The lens and retina take up glucose without insulin. They also carry aldose reductase. That combination makes them vulnerable. Sorbitol build-up and the oxidative stress that follows are long-standing candidate mechanisms in cataract and retinal damage. Aldose reductase inhibitors have been trialed on this basis, with mixed results.

Diabetic neuropathy: Peripheral nerves take up glucose the same way. Research associates polyol pathway activity with slower nerve conduction. Aldose reductase inhibition is still an active research target here (Oates, 2008).

Diabetic nephropathy: Kidney tissue both runs the pathway and makes fructose through it. That locally produced fructose has been implicated in kidney injury in animal models.

One caveat: Much of this is mechanistic and animal-model work, supported by human association data. Aldose reductase inhibitors have given inconsistent results in human trials. The polyol pathway is one contributor among several, not a complete explanation.

Two nutritional approaches have a mechanism relevant to this pathway.

Luteolin: A plant flavone found in celery, parsley, thyme and chamomile. Research suggests it may affect fructokinase activity in preclinical models. That is relevant here because fructokinase sits directly downstream and handles the fructose this pathway produces. The aim is to limit the consequences, not to change the pathway itself. Evidence is preclinical.

Tart cherry: Montmorency cherry is rich in anthocyanins. These have been studied for effects on uric acid and inflammatory markers in small human trials. Evidence for uric acid effects is moderate. There is no evidence of a direct effect on the polyol pathway.

The strongest evidence still sits with the basics. Blood glucose control, good hydration and lower added sugar all act on the triggers rather than the consequences.

At LIV3, we believe polyol pathway activation is one of the most overlooked drivers of metabolic problems. It is overlooked because it works independently of what a person eats.

Addressing it means looking upstream. The question is what happens to fructose once it exists, not how to manage the symptoms it leaves behind.

SugarShield delivers liposomal luteolin alongside tart cherry extract. It is designed to support how the body handles fructose, whether that fructose came from food or was made internally through the polyol pathway.

SugarShield is a food supplement, not a medicine. It is not intended to diagnose, treat, cure, or prevent any disease.

FRUCTOSE METABOLISM GUIDE: The Complete Science of How Fructose Reshapes Your Metabolism

ENDOGENOUS FRUCTOSE: How Your Body Makes Its Own Fructose Without Any Dietary Sugar

FRUCTOKINASE: The Enzyme That Sits Directly Downstream of the Polyol Pathway

URIC ACID HUB: Uric Acid and Fructose: The Metabolic Feedback Loop

• Brownlee, M. (2001). “Biochemistry and molecular cell biology of diabetic complications.” Nature, 414(6865), 813-820.
• Chung, S. S., Ho, E. C., Lam, K. S., & Chung, S. K. (2003). “Contribution of polyol pathway to diabetes-induced oxidative stress.” Journal of the American Society of Nephrology, 14(3 Suppl 3), S233-S236.
• Lanaspa, M. A., Ishimoto, T., Li, N., Cicerchi, C., Orlicky, D. J., Ruzycki, P., Rivard, C., Inaba, S., Roncal-Jimenez, C. A., Bales, E. S., Diggle, C. P., Asipu, A., Petrash, J. M., Kosugi, T., Maruyama, S., Sanchez-Lozada, L. G., McManaman, J. L., Bonthron, D. T., Sautin, Y. Y., & Johnson, R. J. (2013). “Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome.” Nature Communications, 4(2434).
• Oates, P. J. (2008). “Aldose reductase, still a compelling target for diabetic neuropathy.” Current Drug Targets, 9(1), 14-36.
• Yan, L. J. (2018). “Redox imbalance stress in diabetes mellitus: Role of the polyol pathway.” Animal Models and Experimental Medicine, 1(1), 7-13.